EURONEXT-PAR$IPHA

Innate Pharma SA · Q2 2024 earnings

Q2 2024 earnings · · Investor relations

Briefing

IPHA Q2 2024 — extraction skipped

Innate Pharma SA filed Form 6-K (accession 0001598599-24-000086) for Q2 2024, but headline financial numerics could not be extracted automatically: no headline numerics found by parser nor by Financial Datasets fallback. The row is marked as AI-processed so the queue advances; numerics will be filled by Financial Datasets on its next pass.

  • Form 6-K filed; press release body not parseable here.
  • Reason: no headline numerics found by parser nor by Financial Datasets fallback.
  • Numerics rely on the Financial Datasets fallback.

Headline financials

Total Revenue

$6.64M

Previous: $38.6M-82.8%
EPS (adj)

-$0.16

Previous: $0.02-835.9%
Net Income

-$24.8M

Previous: $1.72M-1541.4%
Operating Income

-$26.3M

Previous: -$5.25M-400.9%
Gross Profit

-$16.7M

Previous: $19.6M-185.3%
R&D Expense

$29.1M

Previous: $28.4M+2.3%

Revenue & EPS history

Innate Pharma SA · Revenue · Quarterly

$6.64M

Q2 2024-82.8%vs Q2 2023
Beat estimate in 3 of 10 quarters(30%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 11 quarterly earnings reports · overlaid with Q2 2024

Historical avgQ2 2024

-0.6%

Avg return

Earnings day

-0.1%

Avg return

5 days after

-0.2%

Avg return

30 days after

27%

3 / 11 earnings

Positive

+13.5%

Q4 2019

Best reaction

-8.8%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2026———
Q3 2025-2.4%-6.3%-3.1%
Q2 2024-4.2%-2.7%+37.6%
Q4 2023-2.9%+4.3%-1.8%
Q2 2023-3.9%-3.7%-3.0%
Q4 2022-8.8%-10.7%-11.8%
Q2 2022+2.8%+0.7%+13.5%
Q4 2021+2.6%+2.4%-23.3%
Q2 2021-0.6%-1.7%-7.3%
Q4 2020+0.0%+3.2%-5.1%
Q2 2020-2.6%+1.3%-5.1%
Q4 2019+13.5%+11.5%+7.3%
Q2 2019———
Q4 2018———
Q2 2018———
Q4 2017———
Q2 2017———
Q4 2016———
Q2 2016———
Q4 2015———
Q2 2015———
Q4 2014———
Q2 2014———
Q4 2013———
Q2 2013———
Q4 2012———
Q4 2011———
Q2 2011———
Q4 2010———
Q2 2010———

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro